Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics (NQ: CORT )

58.60 +0.02 (+0.03%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 477,926
Open 58.86
Bid (Size) 57.58 (1)
Ask (Size) 59.20 (1)
Prev. Close 58.58
Today's Range 57.84 - 59.21
52wk Range 20.87 - 61.66
Shares Outstanding 115,926,629
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
For those who appreciate growth without the sticker shock, NASDAQ:CORT is worth considering.
NASDAQ:CORT is showing decent growth, but is still valued reasonably. 
Via Chartmill
In the world of growth stocks, NASDAQ:CORT shines as a value proposition.
Looking for growth without the hefty price tag? Consider NASDAQ:CORT. 
Via Chartmill

Performance

YTD
+142.55%
+142.55%
1 Month
+21.22%
+21.22%
3 Month
+70.15%
+70.15%
6 Month
+85.85%
+85.85%
1 Year
+130.26%
+130.26%

More News

Read More
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via Business Wire
Earnings Preview: Corcept Therapeutics
Via Benzinga
Key Takeaways From Corcept Therapeutics Analyst Ratings
Via Benzinga
Is NASDAQ:CORT suited for high growth investing?
Via Chartmill
NASDAQ:CORT: a strong growth stock preparing for the next leg up?.
Via Chartmill
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via Business Wire
Investors seeking growth at a reasonable cost should explore NASDAQ:CORT.
Via Chartmill
Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast
Via Benzinga
Forecasting The Future: 6 Analyst Projections For Corcept Therapeutics
Via Benzinga
NASDAQ:CORT is not too expensive for the growth it is showing.
Via Chartmill
NASDAQ:CORT: a strong growth stock preparing for the next leg up?.
Via Chartmill
NASDAQ:CORT: a strong growth stock preparing for the next leg up?.
Via Chartmill
NASDAQ:CORT is not too expensive for the growth it is showing.
Via Chartmill
For those who appreciate growth without the sticker shock, NASDAQ:CORT is worth considering.
Via Chartmill
Unveiling 8 Analyst Insights On Corcept Therapeutics
Via Benzinga
CORT Stock Earnings: Corcept Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Why NASDAQ:CORT Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
Investors seeking growth at a reasonable cost should explore NASDAQ:CORT.
Via Chartmill
7 Biotech Stocks to Boost Your Portfolio to Peak Health
Via InvestorPlace
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.